🇪🇺 Sie wollen mehr Transparenz in der EU? Entdecken Sie unsere EU-Recherchen!

Resultate zur PROLIFIC2020 Studie

Ergebnisse der PROLIFIC2020 Studie aus 2020

Anfrage erfolgreich

  • Datum
    21. Januar 2022
  • Frist
    11. Februar 2022
  • 0 Follower:innen
Matthias Lach
Antrag nach EU-Verordnungen 1049/2001 sowie 1367/2006 Sehr geehrte Damen und Herren, auf Basis der Verordnungen 1…
An Europäische Arzneimittel-Agentur Details
Von
Matthias Lach
Betreff
Resultate zur PROLIFIC2020 Studie [#238369]
Datum
21. Januar 2022 11:23
An
Europäische Arzneimittel-Agentur
Status
Warte auf Antwort — E-Mail wurde erfolgreich versendet.
Antrag nach EU-Verordnungen 1049/2001 sowie 1367/2006 Sehr geehrte Damen und Herren, auf Basis der Verordnungen 1049/2001 sowie 1367/2006 bitte ich Sie um Übersendung von Dokumenten, die folgende Informationen enthalten:
Ergebnisse der PROLIFIC2020 Studie aus 2020
Ich weise ausdrücklich darauf hin, dass ich eine Antwort per E-Mail an diese Adresse und nicht über ein Webportal wünsche. Ich möchte Sie um eine Empfangsbestätigung bitten und danke Ihnen für Ihre Mühe! Mit freundlichen Grüßen Matthias Lach Anfragenr: 238369 Antwort an: <<E-Mail-Adresse>> Laden Sie große Dateien zu dieser Anfrage hier hoch: https://fragdenstaat.de/a/238369/ Postanschrift Matthias Lach << Adresse entfernt >> << Adresse entfernt >>
Mit freundlichen Grüßen Matthias Lach
Europäische Arzneimittel-Agentur
Dear Sir/Madam **ASK-105382 ( https://servicedesk.ema.europa.eu/jir... ) - (VY)Resultate zur PROLIFIC2020 Studie …
Von
Europäische Arzneimittel-Agentur
Betreff
[EMA Service Desk] AskEMA ASK-105382 - (VY)Resultate zur PROLIFIC2020 Studie [#238369]
Datum
21. Januar 2022 12:44
Status
Anfrage abgeschlossen
8b223f72-fca9-408a-9d41-755ecad8c0dc__issueType.png
737 Bytes


Dear Sir/Madam **ASK-105382 ( https://servicedesk.ema.europa.eu/jir... ) - (VY)Resultate zur PROLIFIC2020 Studie [#238369] received on 21/Jan/22** Thank you for submitting your request. This is an automated response to confirm that we have received your request; please do not respond directly to this message as this email address is not monitored. A member of Agency staff will now review your request. We will send an acknowledgement of receipt to the email address you have provided, quoting your unique reference number. We endeavour to review all requests as soon as possible, but no later than within 48 hours of receipt, during our normal business hours (see Business hours and holidays ( https://www.ema.europa.eu/en/about-us... )). Should you need to contact us in relation to this request please submit your updated query through the webform ( https://www.ema.europa.eu/en/about-us... ), quoting the ASK reference number given above. Kind regards,
Europäische Arzneimittel-Agentur
PROLIFIC2020 study ASK-105382 Acknowledgement of receipt and start of the procedure Dear Mr Lach, Thank you for c…
Von
Europäische Arzneimittel-Agentur
Betreff
PROLIFIC2020 study ASK-105382 Acknowledgement of receipt and start of the procedure
Datum
28. Februar 2022 10:17
Status
Anfrage abgeschlossen
image001.png
435 Bytes
image002.png
532 Bytes
image003.png
541 Bytes
image004.jpg
5,4 KB


Dear Mr Lach, Thank you for contacting us on 21st January 2022. We hereby acknowledge receipt of your application for access to documents, which was registered on 23rd February 2022 under reference number ASK-105382. We will deal with your request as soon as possible and in accordance with the principles and limits established in Regulation (EC) 1049/2001 regarding public access to European Parliament, Council and Commission documents (the Regulation), as applicable to the EMA pursuant to Article 73 of Regulation (EC) 726/2004. In accordance with the Regulation, you will receive a reply via a secure Eudralink within 15 working days. The Agency may extend this period by a further 15 working days in exceptional circumstances in accordance with the Regulation. Please note that the European Medicines Agency is currently operating within a business continuity plan to ensure operational continuity during the continuing COVID-19 pandemic. Whilst every effort is being made to process your request as soon as possible, you should be aware that due to these exceptional circumstances, we may have to extend the deadline as outlined above. Should such an extension be applied by the Agency, you will be informed at the time. Kind regards,
Europäische Arzneimittel-Agentur
EudraLink - PROLIFIC2020 study ASK-105382 Letter to the requester; +++++++++++++++++++++++++++++++++++++++++++++ Y…
Von
Europäische Arzneimittel-Agentur
Betreff
EudraLink - PROLIFIC2020 study ASK-105382 Letter to the requester;
Datum
4. März 2022 08:22
Status
+++++++++++++++++++++++++++++++++++++++++++++ You have been sent a package by "European Medicines Agency" <<Name und E-Mail-Adresse>> To retrieve your package use the hyperlink below https://eudralink.ema.europa.eu/dl.ph... The package will expire on Thu, 02 Jun 2022 09:22:26 +0200 HOW TO PICK UP YOUR PACKAGE: If the Web address above is highlighted, click on it to open a browser window. You will automatically be taken to the package. If the Web address above is not highlighted, follow these steps: - Open a Web browser window. - Copy and paste the entire Web address into the "location" or "address" bar of the browser. - Press enter. Once you arrive at the Web page, you can access the package. +++++++++++++++++++++++++++++++++++++++++++++
Europäische Arzneimittel-Agentur
PROLIFIC2020 study ASK-105382 - Release letter to the requester and password information Dear Mr Lach, We would l…
Von
Europäische Arzneimittel-Agentur
Betreff
PROLIFIC2020 study ASK-105382 - Release letter to the requester and password information
Datum
4. März 2022 08:23
Status
image001.png
435 Bytes
image002.png
532 Bytes
image003.png
541 Bytes
image004.jpg
5,4 KB


Dear Mr Lach, We would like to inform you that the letter regarding the above request has just been released to you via a secure Eudralink. Please ensure that you download and save the document before the package expires. Please note that you will need to enter a password to access this Eudralink package. Your unique password takes the following format: ASK-XXXX-YYYY It is the ASK reference number for this request (ASK-XXXX, written exactly as it appears in the subject line ) + the year (-YYYY) in which you submitted your request to the Agency. Kind regards,

Ein Zeichen für Informationsfreiheit setzen

FragDenStaat ist ein gemeinnütziges Projekt und durch Spenden finanziert. Nur mit Ihrer Unterstützung können wir die Plattform zur Verfügung stellen und für unsere Nutzer:innen weiterentwickeln. Setzen Sie sich mit uns für Informationsfreiheit ein!

Jetzt spenden!

Europäische Arzneimittel-Agentur
Answer via Eudralink Platform
Von
Europäische Arzneimittel-Agentur
Via
Briefpost
Betreff
Answer via Eudralink Platform
Datum
4. März 2022
Status